Last reviewed 2026-06-01 · How we verify

Lanreotide LP 90

University Hospital, Limoges · Phase 3 active Small molecule Under review Quality 0/100

Lanreotide LP 90 is a Somatostatin analog Small molecule drug developed by University Hospital, Limoges. It is currently in Phase 3 development for Acromegaly, Neuroendocrine tumors (gastroenteropancreatic and thoracic), Carcinoid syndrome.

Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.

Lanreotide LP 90 is a somatostatin receptor type 5 agonist, classified as an agonist drug. It has been studied for the prevention of lymphorrhea in patients undergoing axillary dissection for breast cancer.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Lanreotide LP 90
Sponsor	University Hospital, Limoges
Drug class	Somatostatin analog
Target	Somatostatin receptors (SSTR2, SSTR5)
Modality	Small molecule
Therapeutic area	Oncology; Endocrinology
Phase	Phase 3

Mechanism of action

Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby reducing symptoms and tumor growth in neuroendocrine tumors and acromegaly. The LP (long-acting) formulation provides sustained hormone suppression over extended dosing intervals.

Approved indications

Acromegaly
Neuroendocrine tumors (gastroenteropancreatic and thoracic)
Carcinoid syndrome

Common side effects

Diarrhea
Abdominal pain
Nausea
Cholelithiasis
Injection site reactions
Hyperglycemia

Key clinical trials

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lanreotide LP 90 CI brief — competitive landscape report
Lanreotide LP 90 updates RSS · CI watch RSS
University Hospital, Limoges portfolio CI

Frequently asked questions about Lanreotide LP 90

What is Lanreotide LP 90?

Lanreotide LP 90 is a Somatostatin analog drug developed by University Hospital, Limoges, indicated for Acromegaly, Neuroendocrine tumors (gastroenteropancreatic and thoracic), Carcinoid syndrome.

How does Lanreotide LP 90 work?

Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.

What is Lanreotide LP 90 used for?

Lanreotide LP 90 is indicated for Acromegaly, Neuroendocrine tumors (gastroenteropancreatic and thoracic), Carcinoid syndrome.

Who makes Lanreotide LP 90?

Lanreotide LP 90 is developed by University Hospital, Limoges (see full University Hospital, Limoges pipeline at /company/university-hospital-limoges).

What drug class is Lanreotide LP 90 in?

Lanreotide LP 90 belongs to the Somatostatin analog class. See all Somatostatin analog drugs at /class/somatostatin-analog.

What development phase is Lanreotide LP 90 in?

Lanreotide LP 90 is in Phase 3.

What are the side effects of Lanreotide LP 90?

Common side effects of Lanreotide LP 90 include Diarrhea, Abdominal pain, Nausea, Cholelithiasis, Injection site reactions, Hyperglycemia.

What does Lanreotide LP 90 target?

Lanreotide LP 90 targets Somatostatin receptors (SSTR2, SSTR5) and is a Somatostatin analog.

Drug class: All Somatostatin analog drugs
Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
Manufacturer: University Hospital, Limoges — full pipeline
Therapeutic area: All drugs in Oncology; Endocrinology
Indication: Drugs for Acromegaly
Indication: Drugs for Neuroendocrine tumors (gastroenteropancreatic and thoracic)
Indication: Drugs for Carcinoid syndrome

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing